Explainable Machine Learning Predictions for the Benefit From Chemotherapy in Advanced Non‐Small Cell Lung Cancer Without Available Targeted Mutations
2024

Predicting Chemotherapy Benefits in Lung Cancer Using Machine Learning

Sample size: 461 publication 10 minutes Evidence: moderate

Author Information

Author(s): Shuang Zhao, Xingyu Xiong, Yue Cheng, Mingjing Yu

Primary Institution: West China Hospital, Sichuan University

Hypothesis

Can machine learning models effectively predict chemotherapy benefits for NSCLC patients without targeted mutations?

Conclusion

The study developed a predictive model that can help identify NSCLC patients likely to benefit from chemotherapy, potentially improving their prognosis.

Supporting Evidence

  • The Xgboost model showed an AUC of 0.78, indicating good predictive performance.
  • Patients with a history of surgery had better chemotherapy responses.
  • Higher NLR, PLR, and LDH were associated with poorer survival outcomes.

Takeaway

Researchers created a computer program to help doctors figure out which lung cancer patients might do better with chemotherapy, using simple health information.

Methodology

A retrospective cohort study analyzing NSCLC patients' medical records and using machine learning to develop predictive models.

Potential Biases

Potential confounding factors due to the retrospective nature of the study.

Limitations

The study had a small sample size from a single center and lacked external validation.

Participant Demographics

Median age of participants was 59.2 years, with 313 males and 148 females.

Statistical Information

P-Value

p<0.001

Confidence Interval

95% CI 0.777–0.783

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1111/crj.70044

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication